Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.51 |
| ▸ | ACLY | P53396 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CDK7 | P50613 | 1/20 | 0.46 |
| ▸ | CCNH | P51946 | 1/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.46 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.46 |
| ▸ | S100A9 | P06702 | 4/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | SGK1 | O00141 | 4/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | TYMS | P04818 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16296008 | 0.80 | TDP1 (0.53) | TDP1PFKFB3ACLYCDK1CCNB1 | |
| SCHEMBL16295812 | 0.79 | ACLY (0.48) | PFKFB3ACLYDAO | |
| SCHEMBL30560873 | 0.77 | ALDH1A1 (0.47) | — | |
| SCHEMBL16296178 | 0.77 | ALDH1A1 (0.47) | — | |
| SCHEMBL16296179 | 0.77 | MAPT (0.48) | TDP1 | |
| SCHEMBL16295632 | 0.76 | STS (0.35) | TDP1ACLY | |
| SCHEMBL16296134 | 0.76 | GAA (0.49) | CYP2C9 | |
| SCHEMBL16296067 | 0.73 | ALDH1A1 (0.52) | ACLYCDK1CCNB1CCNA2CCND1 | |
| SCHEMBL30560876 | 0.73 | ALDH1A1 (0.52) | ACLYCDK1CCNB1CCNA2CCND1 | |
| SCHEMBL16295214 | 0.73 | GAA (0.46) | ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3008045-B1 | ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS | ANTABIO SAS (FR) | 2018-05-09 | — | — | EP | claimed |
| US-9914712-B2 | Antibacterial thiazolecarboxylic acids | ANTABIO SAS (FR) | 2018-03-13 | — | — | US | claimed |
| US-20160272601-A1 | Antibacterial Thiazolecarboxylic Acids | ANTABIO SAS (FR) | 2016-09-22 | — | — | US | claimed |
| EP-3008045-A1 | ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS | Antabio SAS (FR) | 2016-04-20 | — | — | EP | claimed |
| WO-2014198849-A1 | ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS | ANTABIO SAS (FR) | 2014-12-18 | — | — | WO | claimed |
| US-12378244-B2 | Diazabicyclooctanones as inhibitors of serine β-lactamases | ANTABIO SAS (FR) | 2025-08-05 | — | — | US | disclosed |
| US-20240391919-A1 | DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES | ANTABIO SAS (FR) | 2024-11-28 | — | — | US | disclosed |
| US-11905286-B2 | Diazabicyclooctanones as inhibitors of serine beta-lactamases | ANTABIO SAS (FR) | 2024-02-20 | — | — | US | disclosed |
| CN-117384155-A | Diazabicyclooctanones as serine beta-lactamase inhibitors | 安塔比奥公司 | 2024-01-12 | — | — | CN | disclosed |
| EP-4272831-A2 | DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES | Antabio SAS (FR) | 2023-11-08 | — | — | EP | disclosed |
| CN-111954671-B | Diazabicyclooctanones as serine beta-lactamase inhibitors | 安塔比奥公司 | 2023-09-01 | — | — | CN | disclosed |
| EP-3833665-B1 | DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES | ANTABIO SAS (FR) | 2023-07-19 | — | — | EP | disclosed |
| EP-3833665-A1 | DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES | Antabio SAS (FR) | 2021-06-16 | — | — | EP | disclosed |
| CN-111954671-A | Diazabicyclooctanones as serine beta-lactamase inhibitors | 安塔比奥公司 | 2020-11-17 | — | — | CN | disclosed |
| WO-2020030761-A1 | DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES | ANTABIO SAS (FR) | 2020-02-13 | — | — | WO | disclosed |
| EP-3008045-B1 | ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS | ANTABIO SAS (FR) | 2018-05-09 | — | — | EP | disclosed |
| US-9914712-B2 | Antibacterial thiazolecarboxylic acids | ANTABIO SAS (FR) | 2018-03-13 | — | — | US | disclosed |
| US-20160272601-A1 | Antibacterial Thiazolecarboxylic Acids | ANTABIO SAS (FR) | 2016-09-22 | — | — | US | disclosed |
| EP-3008045-A1 | ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS | Antabio SAS (FR) | 2016-04-20 | — | — | EP | disclosed |
| WO-2014198849-A1 | ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS | ANTABIO SAS (FR) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905286-B2 | Diazabicyclooctanones as inhibitors of serine beta-lactamases | STS, BCKDK, PEPD | TDP1 2813/4885PFKFB3 402/4885ACLY 2303/4885 |
| US-20240391919-A1 | DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES | STS, BCKDK, PEPD | TDP1 2813/4885PFKFB3 402/4885ACLY 2303/4885 |
| US-12378244-B2 | Diazabicyclooctanones as inhibitors of serine β-lactamases | STS, PEPD, BCKDK | TDP1 2844/4885PFKFB3 386/4885ACLY 2175/4885 |
| US-20160272601-A1 | Antibacterial Thiazolecarboxylic Acids | ME1, TALDO1, COASY | TDP1 2507/4885PFKFB3 3350/4885ACLY 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.